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ABSTRACT
Introduction: Studies comparing direct-acting
insulin analogs (DAIs) in terms of effectiveness
and long-term safety are scarce. Our aim was to
explore these variables in clinical practice
among patients with type 1 diabetes,
including the elderly and those with renal
impairment.
Methods: We linked four national registers in a
population-based cohort study. Patients with
type 1 diabetes and continuous use of all
currently available DAIs (lispro, aspart, or
glulisine) in 2005–2013 were monitored for up
to 7.5 years. Inverse probability of treatment
weighting was used to adjust for differences in
baseline characteristics between treatment
groups. Unadjusted mean HbA1c and weights
were plotted. Hazard ratios and 95% confidence
intervals of cardiovascular events (CVEs) and
mortality were estimated using Cox
proportional hazards regression models.
Results: We included 41,165 patients—14,047
lispro, 26,813 aspart, and 305 glulisine users. At
baseline, the mean age was highest among
glulisine users (49.4 years), followed by
41.0 years for lispro users and 40.1 years for
aspart users. A total of 9.2% of the patients were
65 years or older. Diabetes duration was shortest
among glulisine users (11.6 years), followed by
15.4 years for aspart users and 19.5 years for lispro
users. The mean HbA1c and weights during the
follow-up period were similar. The numerical
differences at baseline were subsequently
adjusted for. There were no significant
differences between groups regarding
hyperglycemia requiring hospitalization, CVE,
or mortality, while Cox regression suggested
lower rates of hypoglycemia among glulisine
users. Severe hypoglycemia was more common,
and severe hyperglycemia was less common
among patients aged 65 years or older, while
severe hypoglycemia and hyperglycemia were
more common in patients with low renal
function (estimated glomerular filtration rate).
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Conclusion: There were no pronounced
differences in effectiveness and long-term
cardiovascular safety and mortality between
the DAIs, although there were some
differences in clinical characteristics between
patients using the three types of insulin. Severe
hypoglycemia was more common among older
patients, while severe hypoglycemia and
hyperglycemia were more common among
patients with impaired renal function.
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INTRODUCTION
Direct-acting insulin analogs (DAIs) are a
cornerstone of contemporary type 1 diabetes
treatment [1]. Insulin lispro was approved for
use in the mid-1990s, making it the first DAI to
enter the market. Insulin aspart became
available in 1999 and insulin glulisine in
2004. Both before and after approval of each
DAI, many clinical trials and studies have
shown non-inferiority and some clinical
advantages over ordinary human insulin,
including fewer doses, increased flexibility,
less hypoglycemia, and greater
cost-effectiveness [2, 3]. Only a few studies
have directly compared the clinical efficacy of
various DAIs [4, 5] and none have addressed
cardiovascular safety.
Long-term, real-life safety data concerning
the impact of DAIs on hard endpoints, such as
cardiovascular events (CVEs) and mortality are
lacking, particularly among elderly patients and
those with renal impairment. The aim of this
study was to explore the long-term effectiveness
on glycemic control, weight, and safety of DAIs
in routine clinical practice among patients with
type 1 diabetes, particularly elderly patients and
those with renal impairment. We conducted a
population-based longitudinal cohort study
linking data from the Swedish National
Diabetes Register (NDR) with other databases
to capture information about hospitalization
and cause of death.
METHODS
The Regional Ethical Review Board in
Gothenburg approved the study, which was
conducted in accordance with the Helsinki
Declaration of 1975, as revised in 2013. All
patients gave their informed consent prior to
inclusion.
Databases
The NDR was launched in 1996 to enable local
quality control and regional benchmarking
against national treatment guidelines [6].
Physicians and nurses from hospitals and
primary healthcare centers nationwide report
annually to the NDR. Body mass index (BMI),
HbA1c, type of diabetes, age at onset, and other
clinical data were obtained from the NDR. The
Prescribed Drug Register (PDR) fully covers all
drug prescriptions (pharmaceutical agents and
amounts) filled at Swedish pharmacies. The
Cause of Death Register contains information
about mortality and date of death. The National
Patient Register focuses on diagnoses. Data
concerning place of birth and educational
level were obtained from the Longitudinal
Integration Database for Health Insurance and
the Labor Market Studies register. These
databases have recently been reviewed and
validated [7].
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Patients, Study Period, Follow-Up,
and Censoring
We included patients with type 1 diabetes who
were at least 18 years old and had used DAIs
continuously for at least 1 year (Fig. 1). Latent
autoimmune diabetes of adults (LADA) is also
reported as type 1 diabetes in the NDR. The first
pick up of a DAI in the PDR was defined as the
index date. Continuous use was defined as having
filled at least three ordinary or 19 multi-dose
prescriptions during the first year after the index
date. This multi-dose, which is called ApoDos
(Apoteket AB), is a parallel system dispensed at
shorter intervals (usually twice per month), and
has been a source of confusion when used
together with ordinary prescriptions [8]. Thus,
we excluded patients who had picked up both
ordinary DAI and ApoDos prescriptions. The
study period was July 1, 2005 to December 31,
2014. Patients were monitored until the end of
the study period or the occurrence of a censoring
event. Start of follow-up was defined as the date
that the third insulin prescription was picked up.
Censoring events included picking up a new type
of DAI, death, emigration, and the occurrence of
a safety outcome (see below).
Patient Characteristics
Variables measured at baseline (index date)
included age, gender, diabetes duration,
smoking, physical inactivity (exercising less
than once a week), higher (post-secondary)
education, history of hyperglycemia or
hypoglycemia, history of cardiovascular
disease (CVD), and type of basal insulin. The
latest values for HbA1c, BMI, weight, blood
pressure, blood lipids (total cholesterol,
low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, and
triglycerides), and estimated glomerular
filtration rate (eGFR) up to 12 months before
the index date were used. The Modification of
Diet in Renal Disease (MDRD) study equation
[9] was used to calculate eGFR. Renal
impairment was defined as eGFR\60 mL/min/
1.73 m2. HbA1c analyses and other laboratory
tests were performed locally. During the study
period, HbA1c analyses were quality assured
nationwide by means of regular calibration with
the high-performance liquid chromatography
Mono-S (GE Healthcare) method.
History of coronary heart disease (CHD) was
defined as diagnosis of ischemic heart disease
(I20–I25), treatment with percutaneous
coronary intervention (PCI) or treatment with
coronary artery bypass graft (CABG) prior to the
index date. History of CVD was defined as
diagnosis of stroke or peripheral vascular disease
prior to the index date, or history of CHD.
History of atrial fibrillation, congestive heart
failure, stroke, kidney failure, hyperglycemia,
and hypoglycemia was defined in a similar
manner using International Classification of
Diseases (ICD) 10 codes (Table 1).
Outcomes
We examined annual changes in mean HbA1c
and weight. The safety outcomes were
hospitalization due to hyperglycemia or
hypoglycemia, kidney failure, CVEs (CHD,
CVD, stroke, atrial fibrillation, or congestive
heart failure) or death. Except for death, these
outcomes are defined using the same ICD codes
as described in the section on patient
characteristics (Table 1).
Statistical Methods
Missing baseline data were assigned values by
means of multiple imputations from a
multivariate normal model using a Monte
Diabetes Ther (2016) 7:561–573 563
Carlo Markov chain approach, creating ten data
sets. The percentage of missing data ranged
from zero (age, gender, treatment, and prior
conditions) to 76% (physical activity).
Propensity scores [10] were estimated using a
multinomial generalized boosted regression
model [11], including all variables in Table 2
for each imputed data set. The inverse of the
average propensity score was used for inverse
probability of treatment weighting to adjust for
differences in baseline characteristics between
treatment groups.
Patient characteristics at baseline were
evaluated by means of standard descriptive
Fig. 1 Patient selection ﬂow chart. Stages of inclusion and exclusion, used databases used. A.P. ApoDos prescription, DAI
direct-acting insulin analogs, NDR National Diabetes Register, O.P. ordinary prescription, PDR Prescribed Drug Register
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statistics. Variations between the treatment
groups were evaluated graphically using the
maximal pairwise standardized difference.
Unadjusted mean HbA1c and weights were
plotted by means of penalized B-splines with
95% confidence intervals (CIs). The treatment
groups were compared with respect to CVEs and
mortality by fitting a weighted Cox
proportional hazards model with standard
errors that were deemed to reflect the
weighted analysis. We used SAS version 9.4
(SAS Institute Inc.) and R version 3.1.0 (The R
Foundation) to perform the statistical
calculations.
RESULTS
We included 41,165 patients: 14,047 lispro,
26,813 aspart, and 305 glulisine users. We
used inverse probability of treatment
weighting to adjust for differences in baseline
characteristics between the treatment groups.
Prior to the adjustment, there were numerical
differences between the groups. Mean age was
highest among glulisine users (49.4 years),
followed by 41.0 years among lispro users and
40.1 years among aspart users. A total of 9.2% of
the patients were 65 years or older. Diabetes
duration was shortest among glulisine users
Table 1 ICD groups and corresponding codes
Group number and
name




1. PCI FNG0, FNG00, FNG02, FNG05, FNG06, FNG10, FNG30, FNG96
2. CABG FNA0, FNA00, FNA10, FNA20, FNA96, FNB00, FNB20, FNB96, FNC10, FNC20, FNC30,
FNC40, FNC50, FNC60, FNC96, FND10, FND20, FND96, FNE00, FNE10, FNE20,
FNE96, FNF00, FNF10, FNF20, FNF30, FNF96
3. Stroke I61, I63, I64, I67.9
4. Peripheral vascular
disease
I70.2, I73.1, I73.9, I79.2, E10.5, E11.5, E14.5. NHQ09, NHQ11, NGQ09, NGQ11, NGQ99,
NFQ09, NFQ19, NFQ99, NEQ19, NEQ99




7. Kidney failure N18, N19
8. Hypoglycemia E100, E106A, E110, E110C, E110X, E116A, E120, E130, E140, E159, E160, E161 W, E162,
R402
9. Hyperglycemia E100A, E100B, E100D, E100X, E101, E101A, E101B, E101D, E101X, E110, E110A, E110B,
E110D, E110X, E111, E111A, E111B, E111D, E111X, R739
A. CHD = groups 0–2
B. CVD = groups 0–4
CABG coronary artery bypass graft, CHD coronary heart disease, CVD cardiovascular disease, ICD10 International
Classiﬁcation of Diseases 10, PCI percutaneous coronary intervention
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Table 2 Baseline characteristics of patients treated with lispro, aspart, and glulisine
Characteristics Lispro (n5 14,047) Aspart (n5 26,813) Glulisine (n5 305)
Age, years 41.0 (15.7) 40.1 (18.3) 49.4 (18.3)
Aged 65 years or older, n 1002 (7.1) 2694 (10.0) 75 (24.6)
Female, n 6323 (45.0) 11,210 (41.8) 127 (41.6)
Diabetes duration, years 19.5 (12.7) 15.4 (14.8) 11.6 (14.7)
Total cholesterol, mmol/L 4.8 (0.9) 4.8 (0.9) 4.8 (1.0)
Triglycerides, mmol/L 1.1 (0.7) 1.2 (0.9) 1.4 (1.1)
HDL, mmol/L 1.7 (0.5) 1.6 (0.5) 1.5 (0.5)
HbA1c, mmol/mol 63.6 (13.4) 64.1 (14.6) 70.3 (17.9)
BMI, kg/m2 25.7 (3.7) 25.6 (3.9) 26.3 (4.9)
Systolic BP, mmHg 128.4 (15.8) 130.0 (16.7) 132.3 (17.0)
Diastolic BP, mmHg 74.4 (9.0) 74.3 (9.1) 75.2 (9.3)
eGFR, mL/min/1.73 m2 86.7 (23.4) 86.7 (28.4) 90.2 (26.2)
Renal impairment, n 5986 (42.6) 9268 (34.6) 135 (44.3)
Smoker, n 875 (12.7) 1559 (14.3) 24 (15.1)
Higher education, n 4969 (35.6) 7605 (28.7) 78 (26.0)
Physical inactivity, n 776 (20.8) 1344 (22.0) 20 (16.9)
Insulin pump (CSII), n 1144 (18.3) 761 (8.1) 3 (2.4)
Long-acting insulin, n
Human (NPH) 3793 (27) 7619 (28.4) 63 (20.7)
Glargine 7757 (55.2) 12,886 (48.1) 137 (44.9)
Detemir 720 (5.1) 2964 (11.1) 7 (2.3)
Other 1777 (12.7) 3344 (12.5) 98 (32.1)
History of …, n
Ischemic heart disease 296 (2.1) 625 (2.3) 9 (3.0)
Atrial ﬁbrillation 159 (1.1) 389 (1.5) 12 (3.9)
Myocardial infarction 266 (1.9) 590 (2.2) 11 (3.6)
Unstable angina 477 (3.4) 964 (3.6) 17 (5.6)
PCI 189 (1.3) 427 (1.6) 13 (4.3)
CABG 198 (1.4) 413 (1.5) 6 (2.0)
Peripheral vascular disease 304 (2.2) 646 (2.4) 7 (2.3)
Stroke 144 (1.0) 382 (1.4) 7 (2.3)
Congestive heart failure 151 (1.1) 365 (1.4) 9 (3.0)
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(11.6 years), followed by 15.4 years for aspart
users and 19.5 years for lispro users (Table 2).
Mean HbA1c was 70.3 mmol/mol among
glulisine users, 63.6 mmol/mol among lispro
users, and 64.1 mmol/mol among aspart users.
A higher proportion of glulisine users had a
history of CHD (8.2%), followed by 4.4%
among lispro users and 4.2% among aspart
users. A higher proportion of glulisine users had
a history of CVD (10.5%), followed by 7.4%
among aspart users and 6.5% among lispro
users. A lower proportion of glulisine users,
however, had a history of severe hypoglycemia
(4.3%), followed by 6.2% among aspart users
and 7.8% among lispro users. A lower
proportion of glulisine users had a history of
severe hyperglycemia (5.6%), followed by 8.5%
among aspart users and 8.6% among lispro
users. The differences between the groups were
all adjusted for by means of weighting.
The mean follow-up period was shortest for
glulisine (2.5 years), followed by 5.8 years for
aspart users and 6.4 years for lispro users
(Table 3). The absolute number of events was
very low in the glulisine group, ranging from 0
to 13 (Table 3). The (unadjusted) mean HbA1c
and weight during the follow-up period were
similar (Figs. 2, 3). No significant differences
emerged between the treatment groups
regarding risk of hyperglycemia requiring
hospitalization, CVD or mortality. Cox
regression suggested lower risks among glulisine
users for severe hypoglycemia (HR 0.16, CI:
0.04–0.64 vs. lispro users and HR 0.16, CI:
0.04–0.62 vs. aspart users). Cox regression
suggested lower risks among glulisine users for
heart failure (HR 0.08, CI: 0.02–0.31 vs. lispro
users and HR 0.11, CI: 0.02–0.54 vs. aspart users;
Table 4). Cox regression also suggested a lower
risk of stroke (HR 0.80, CI: 0.68–0.93) but a
higher risk of hyperglycemia (HR 1.13, CI:
1.03–1.23) among aspart users than lispro users.
For patients 65 years of age or older, the risk
of CVD (HR 0.85, CI: 0.74–0.96), stroke (HR
0.61, CI: 0.46–0.81), and heart failure (HR 0.79,
CI: 0.65–0.95) was lower among aspart users
than lispro users (Table 5). Among these
patients, the risk of heart failure remained
significantly lower in the glulisine group
compared with the lispro group. For elderly
patients, Cox regression suggests that glulisine
users were at lower risk of kidney failure (HR
0.12, CI: 0.02–0.88 vs. lispro and HR 0.12, CI:
0.01–0.79 vs. aspart). Overall, severe
hypoglycemia was more common, and severe
hyperglycemia was less common among
patients age 65 year or older than among
younger patients (HR 1.54, CI: 1.34–1.76 and
HR 0.84, CI: 0.73–0.97). Adjusting for
confounders did not change this result.
Among patients with renal impairment
(Table 6), glulisine users had a lower risk of
CVD (HR 0.14, CI: 0.03–0.68 vs. lispro; HR 0.13,
CI: 0.03–0.66 vs. aspart) and CHD (HR 0.08, CI:
Table 2 continued
Characteristics Lispro (n5 14,047) Aspart (n5 26,813) Glulisine (n5 305)
Hypoglycemia 1093 (7.8) 1671 (6.2) 13 (4.3)
Hyperglycemia 1203 (8.6) 2289 (8.5) 17 (5.6)
Data are presented as means (standard deviations) unless otherwise stated
BMI body mass index, BP blood pressure, CABG coronary artery bypass graft, CSII continuous subcutaneous insulin
infusion, eGFR estimated glomerular ﬁltration rate, HDL high-density lipoprotein, NPH neutral protamine Hagedorn, PCI
percutaneous coronary intervention
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0.01–0.70 vs. lispro; HR 0.09, CI: 0.01–0.72 vs.
aspart). For the three treatment groups taken
together, the risk of severe hypoglycemia and
hyperglycemia was higher among patients with
low renal function than those with normal
renal function (HR 1.30, CI: 1.18–1.42 and HR
1.92, CI: 1.76–2.09, respectively). Adjusting for
confounders eliminated any significant
difference in the risk of hypoglycemia between
patients with low renal function and those with
normal renal function (HR 1.12, CI: 1.00–1.25).
The risk of hyperglycemia, however, remained
higher among patients with low renal function
(HR 1.77, CI: 1.59–1.98).
Table 3 Follow-up period, number of events and incidence per 1000 person years
Event Lispro (n 5 14,047) Aspart (n5 26,813) Glulisine (n5 305)
Deaths 563 (6.2) 1223 (7.9) 6 (7.7)
Fatal CHD 198 (2.2) 444 (2.9) 0 (0.0)
Fatal CVD 225 (2.5) 505 (3.2) 0 (0.0)
CHD 898 (10.3) 1676 (11.1) 9 (11.7)
CVD 1283 (14.9) 2352 (15.9) 13 (17)
Stroke 285 (3.2) 441 (2.9) 2 (2.6)
Heart failure 374 (4.2) 743 (4.8) 3 (3.9)
Kidney failure 385 (4.3) 724 (4.7) 3 (3.9)
Hypoglycemia 706 (8.0) 1299 (8.6) 3 (3.9)
Hyperglycemia 929 (10.7) 1946 (13.0) 3 (3.9)
Maximum follow-up time, years 7.5 7.5 7
Mean follow-up time, years 6.4 5.8 2.5
Median follow-up time, years 6.8 6.6 2.7
Values are presented as number of events (incidence per 1000 person-years) unless otherwise stated
CHD coronary heart disease, CVD cardiovascular disease
Fig. 2 Average HbA1c during follow-up period among
patients treated with lispro, aspart, and glulisine. HbA1c in
mmol/mol. Blue lispro; red aspart; green glulisine. Shaded
areas represent 95% conﬁdence intervals
Fig. 3 Average weight during follow-up period among
patients treated with lispro, aspart, and glulisine. Weight in
kilograms. Blue lispro; red aspart; green glulisine. Shaded
areas represent 95% conﬁdence intervals
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DISCUSSION
This observational study of 41,165 patients with
type 1 diabetes who were monitored up to
7.5 years provides information about the
long-term effectiveness and safety of DAIs. The
results confirm that there are no differences in
mean HbA1c or weight between the three DAI
groups during the follow-up period. The DAIs
are equally safe in terms of CVD and all-cause
Table 4 Risks of death and hospitalization
Event Aspart vs. lispro Glulisine vs. lispro Glulisine vs. aspart
Total mortality 1.04 (0.94, 1.16) 0.56 (0.19, 1.66) 0.54 (0.18, 1.58)
CHD 0.95 (0.87, 1.03) 0.49 (0.19, 1.27) 0.52 (0.20, 1.34)
Fatal CHD 1.06 (0.90, 1.25) N/A N/A
CVD 0.94 (0.88, 1.01) 0.56 (0.26, 1.24) 0.60 (0.28, 1.31)
Fatal CVD 1.04 (0.89, 1.23) N/A N/A
Stroke 0.80 (0.68, 0.93)a 0.50 (0.12, 2.08) 0.62 (0.14, 2.59)
Heart failure 0.93 (0.82, 1.05) 0.08 (0.02, 0.31)a 0.11 (0.02, 0.54)a
Kidney failure 1.07 (0.95, 1.22) 0.69 (0.11, 4.30) 0.57 (0.09, 3.49)
Hypoglycemia 1.03 (0.93, 1.15) 0.16 (0.04, 0.64)a 0.16 (0.04, 0.62)a
Hyperglycemia 1.13 (1.03, 1.23)a 0.69 (0.17, 2.73) 0.61 (0.15, 2.42)
Values are presented as estimated hazard ratios (95% conﬁdence intervals)
CHD coronary heart disease, CVD cardiovascular disease, N/A not available
a P value\0.05
Table 5 Risks of death and hospitalization: subgroup analysis among patients age 65 or older
Event Aspart vs. lispro Glulisine vs. lispro Glulisine vs. aspart
Total mortality 0.46 (0.80, 1.18) 0.82 (0.26, 2.60) 0.87 (0.28, 2.73)
CHD 0.88 (0.76, 1.03) 0.67 (0.28, 1.61) 0.76 (0.32, 1.81)
Fatal CHD 0.91 (0.70, 1.20) N/A N/A
CVD 0.85 (0.74, 0.96)a 0.68 (0.33, 1.43) 0.81 (0.39, 1.68)
Fatal CVD 0.89 (0.69, 1.15) N/A N/A
Stroke 0.61 (0.46, 0.81)a 0.82 (0.20, 3.49) 1.35 (0.32, 5.64)
Heart failure 0.79 (0.65, 0.95)a 0.22 (0.06, 0.82)a 0.28 (0.08, 1.03)
Kidney failure 1.11 (0.85, 1.46) 0.12 (0.02, 0.88)a 0.12 (0.01, 0.79)a
Hypoglycemia 1.12 (0.83, 1.50) 1.24 (0.33, 4.71) 1.11 (0.30, 4.14)
Hyperglycemia 0.94 (0.68, 1.29) N/A N/A
Values are presented as estimated hazard ratios (95% conﬁdence intervals)
CHD coronary heart disease, CVD cardiovascular disease, N/A not available
a P value\0.05
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mortality. However, for the population with
renal impairment, glulisine was associated with
a lower risk of CVD. The risk of glulisine
treatment for severe hypoglycemia and heart
failure may have been lower in both the overall
and elderly population. The sub-analysis of the
elderly population also found that treatment
with glulisine was associated with a lower risk of
kidney failure. The results suggested a lower risk
of stroke and a higher risk of hyperglycemia
among aspart than lispro users, as well as a
lower risk of CVD, stroke, and heart failure in
the elderly cohort. Hypoglycemia requiring
hospitalization was more common, and severe
hyperglycemia was less common among
patients aged 65 years or older than among
younger patients. Both severe hypoglycemia
and severe hyperglycemia were more common
among patients with low renal function than
those with normal renal function.
All new treatment for hyperglycemia must
be evaluated with respect to cardiovascular
safety and mortality [12]. To the best of our
knowledge, no cardiovascular outcome trials
have been conducted with DAIs, and no
prospective studies have addressed differences
in long-term safety between the three available
options. The main reasons are no doubt their
appearance in the 1990s and the early 2000s
before Sweden adopted a new policy for
introduction of pharmaceutical treatment. The
NDR, additional quality registers, and similar
databases should be used to evaluate insulin
and other treatment as a way of verifying safety
and detecting phenomena for more detailed
exploration in future studies. Another objective
of such surveys is to establish a basis for
discussion of indications, reimbursement and
price.
Based on these results, insulin glulisine
would seem to be superior to the other DAIs
in terms of safety, especially in view of the
impressive hazard ratios, all of which imply a
fivefold-to-tenfold reduction in risk for the
outcomes. Are the differences found by the
present study accurate? The answer is ‘‘maybe,’’
Table 6 Risks of death and hospitalization: subgroup analysis among patients with renal impairment
Event Aspart vs. lispro Glulisine vs. lispro Glulisine vs. aspart
Total Mortality 1.24 (0.97, 1.59) 0.77 (0.15, 4.12) 0.62 (0.12, 3.29)
CHD 0.98 (0.80, 1.20) 0.08 (0.01, 0.70)a 0.09 (0.01, 0.72)a
Fatal CHD 1.23 (0.84, 1.80) N/A N/A
CVD 1.04 (0.87, 1.23) 0.14 (0.03, 0.68)a 0.13 (0.03, 0.66)a
Fatal CVD 1.16 (0.82, 1.65) N/A N/A
Stroke 0.93 (0.62, 1.38) N/A N/A
Heart failure 0.97 (0.74, 1.28) 0.20 (0.02, 1.71) 0.21 (0.02, 1.73)
Kidney failure 1.19 (0.96, 1.47) 2.17 (0.37, 12.57) 1.82 (0.32, 10.54)
Hypoglycemia 1.16 (0.79, 1.69) 0.57 (0.07, 4.99) 0.49 (0.06, 4.27)
Hyperglycemia 1.15 (0.81, 1.64) N/A N/A
Values are presented as estimated hazard ratios (95% conﬁdence intervals)
CHD coronary heart disease, CVD cardiovascular disease, N/A not available
a P value\0.05
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but caution needs to be exercised not to
conclude that any such differences definitely
reflect effects of glulisine. For example, the
results suggest a more than fivefold reduction of
the risk for heart failure among the glulisine
group compared to the lispro and aspart groups,
even though the effect on HbA1c is the same. If
such a reduction in risk is to be attributed to
properties of insulin glulisine, there should be
evidence of differences in the pharmacological
properties of the DAIs. Pharmacological effects
and their clinical consequences were reviewed
just recently [3]. The general view is that the
effects of the three DAIs are highly comparable,
with rapid pharmacokinetic (PK) and
time-action profiles, although glulisine has
been suggested to have a slightly faster onset
of action [13]. A trial with insulin lispro and the
co-administration of hyaluronidase, which
accelerates onset, indicated that a more rapid
PK profile could improve control of
postprandial hyperglycemia without increasing
the risk of hypoglycemia [14]. In other words,
faster onset could reduce glucose variability.
However, it is still unclear whether glucose
variability increases the risk for diabetic vascular
complications [15]. Furthermore, it is unlikely
that minor differences in PKs would translate
into a pronounced reduction in the risk of heart
failure.
The number and the mean follow-up time
for glulisine users were also very limited and
relatively short compared with those among the
other two groups of DAI users. As a result, only
three patients in the glulisine group had a heart
failure outcome, as opposed to 374 in the lispro
group and 743 in the aspart group. There were
even fewer events for the sub-analyses. Thus, it
is very difficult to objectively compare the risks
of outcomes such as heart failure between the
three treatment groups. In other words, the
observed reduction in risk is more likely to have
been a result of unobserved confounding than
simply an effect of glulisine. The same line of
reasoning holds for the other outcomes where
Cox regression suggested that glulisine was safer
than the remaining DAIs.
A confounding factor that may be of some
importance is the probability that many insulin
lispro and aspart users who were included at
baseline in 2005 had already been taking DAIs
for many years. Insulin glulisine, on the other
hand, had just been made commercially
available. Thus, users were generally
glulisine-naive at baseline. Most glulisine
users, however, had previously taken human
insulin or another DAI.
Aspart was associated with more favorable
outcomes than lispro regarding stroke among
the overall cohort and regarding CVD, stroke,
and heart failure among the elderly cohort. On
the other hand, a higher risk of hyperglycemia
was associated with aspart than lispro. As
mentioned earlier, there is no known
difference in pharmacological effect between
these two types of insulin [3]. Thus, these
differences are likely due to unobserved
confounding.
The only way to confirm whether the
observed differences between the safeties of
the three DAIs are due to confounding is to
conduct a randomized clinical trial (RCT).
However, the number of patients and the
duration of exposure needed for such a study
in order to assess cardiovascular endpoints
would probably deter most sponsors. As a
result, an RCT of this type is improbable any
time soon. Future observational studies are
more likely to provide additional data about
cardiovascular safety with the types of insulin
that are currently available.
Well performed observational studies have
been shown to generate results that are
comparable to an RCT [16], although not
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everyone agrees [17]. The most important
limitation of an RCT is the possible lack of
external validity. Pharmaceutical agents are
frequently used outside of the characteristics
of the populations treated in phase 3 programs
before registration—hence, our rationale for the
sub-analyses in this study of elderly patients
and those with reduced renal function.
The major strengths of this study are its
nationwide scope, the large number of patients
with type 1 diabetes, the relatively long
follow-up period, and the many covariates
used in the multivariate analyses. As
mentioned earlier, the relatively small number
and mean follow-up period of insulin glulisine
users were limiting factors. The possible
influence of other unknown confounding
factors that we were unable to account for was
also limitations. For example, doses of the
various types of insulin, the number of
injections, titration algorithms for basal
insulin, plasma glucose levels, and other
pharmaceutical treatments was not taken into
consideration. Such factors could certainly
influence the occurrence of severe
hypoglycemia, especially nocturnal,
potentially leading to CVD and sudden death.
Swedish patients with type 1 diabetes are
encouraged to titrate doses of insulin on a daily
basis, based on their individual requirements,
diet, physical activity, and self-monitored
plasma glucose measurements. Furthermore,
more insulin than needed is frequently
prescribed to avoid running out. Thus, the
PDR does not fully reflect the insulin doses
that have actually been taken. For this reason,
we refrained from using crude measures such as
dispensed daily doses in this study.
Nevertheless, the most important
determinants of insulin requirement—HbA1c,
BMI, and renal function—were quite
comparable and were adjusted for.
CONCLUSIONS
In conclusion, we did not find any pronounced
differences in effectiveness, long-term
cardiovascular safety or mortality between the
three available DAIs. Future studies should
address the observed differences in the risk of
hospitalization for hypoglycemia,
hyperglycemia, stroke, and heart failure. The
safety profile was also similar in the various
subgroups, although the risk of severe
hypoglycemia was more common and severe
hyperglycemia was less common among elderly
patients. Both severe hypoglycemia and severe
hyperglycemia were observed more frequently
among patients with low renal function.
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